ORGS.US Orgenesis Inc

Healthcare Biotechnology USA Stocks
0.3750 USD
Close of Nov 16, 2026
0.0004 0.9100
Market cap
USD 3.67M
P/E
-
P/B
1.26x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is ORGS.US undervalued?

Graham number

The Graham number of Orgenesis Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orgenesis Inc fundamental analysis

No fundamental analysis for Orgenesis Inc yet.

Orgenesis Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orgenesis Inc

Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include a…

Full company profile